TheraRadar
Data updated: May 26, 2026

AVANAFIL

Phosphodiesterase 5 Inhibitors
Urology Approved 2024-06-14

Avanafil is a medication used for adult men who experience erectile dysfunction. It helps patients achieve an erection by facilitating blood flow into the penis during sexual activity. This drug belongs to a class of medications known as PDE5 inhibitors and is prescribed to help manage the physical symptoms of this condition.

Source: FDA Label • HETERO LABS LTD V • Phosphodiesterase 5 Inhibitor

How AVANAFIL Works

Avanafil works by blocking the PDE5 enzyme, which normally breaks down a substance called cGMP in the penis. By preventing this breakdown, the drug enhances the effects of nitric oxide released during sexual stimulation, leading to smooth muscle relaxation and increased blood flow. Because it targets the natural chemical response to arousal, the medication requires sexual stimulation to produce an effect.

Source: FDA Label
1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2024-06-14
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: AVANAFIL

AVANAFIL Approval History

2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2024 to 2024
Jun 2024 ORIGINAL
Update

What AVANAFIL Treats

1 indications

AVANAFIL is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Erectile Dysfunction
Source: FDA Label

AVANAFIL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

MoA expansion candidates

4

Same target(s), different indications — where else is this mechanism being explored?

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Unlock 5 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AVANAFIL

3 of 8

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CAVERJECT IMPULSE
ALPROSTADIL
1 shared
Pfizer
Shared indications:
Erectile Dysfunction
CIALIS
TADALAFIL
1 shared
Eli Lilly
Shared indications:
Erectile Dysfunction
EDEX
ALPROSTADIL
1 shared
ENDO OPERATIONS
Shared indications:
Erectile Dysfunction
📋

Clinical Trial Registry

14 trials
Trial Sponsor ID Phase Status Title
NCT02503306 CEDAR AVANAL07163 U1111-1167-6889 Ph 3 completed Efficacy and Tolerability Study of Avanafil in Russia
NCT01768676 results posted TA-401 Ph 4 completed Study Evaluating the Effects of Avanafil on Semen Parameters
NCT02477436 Avanafil-Korea Ph 2 completed Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction
NCT00895011 results posted TA-303 Ph 3 completed Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
NCT00809471 REVIVE-D results posted TA-302 Ph 3 completed Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
NCT00853606 results posted TA-314 Ph 3 completed Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
NCT00790751 REVIVE results posted TA-301 Ph 3 completed Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
NCT01054261 TA-013 Ph 1 completed To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.
NCT00769041 TA-140 Ph 1 completed A Thorough EKG Safety Study of TA-1790 (Avanafil)
NCT01095601 TA-020 Ph 1 completed Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects
NCT01054430 avanafil TA-012 Ph 1 completed To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.
NCT01054859 TA-015 Ph 1 completed A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.
NCT00903981 ALERT CWP-AVA-301 Ph 3 completed Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil
NCT00770042 TA-011 Ph 1 completed To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AVANAFIL FDA Label Details

Indications & Usage

AVANAFIL is indicated for the treatment of Erectile Dysfunction.

Looking for the branded version?

STENDRA

Full clinical data, patents, trials, and competitive landscape for avanafil.

See STENDRA

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.